Anti-Human CD25 (IL-2Rα) [Clone 7G7B6] — Purified in vivo GOLD™ Functional Grade

Clone 7G7B6 is a mouse monoclonal antibody specific for human CD25 (IL-2R?) that is used in in vivo mouse studies primarily to target CD25-expressing human cells, such as in models of lymphoma.

Key applications and use-case details include:

• Radioimmunotherapy in xenograft models: In a widely cited study, 7G7B6 was conjugated to the radioactive isotope Yttrium-90 (^90Y), producing ^90Y-7G7B6 for radioimmunotherapy experiments. Nude mice with subcutaneous human lymphoma (SUDHL-1, a CD25^+ T-cell lymphoma line) xenografts were treated with this conjugate. Mice received single intravenous doses of ^90Y-7G7B6, which significantly prolonged survival and resulted in a higher rate of tumor-free, long-term survivors compared to controls. The study included biodistribution, survival analysis, and comparison with an isotype-matched control antibody.

• Immunoreactivity and modulation studies: In supporting work, radiolabeled 7G7B6 was evaluated for its ability to bind CD25^+ cells (kit225IG3) and its effect on CD25 surface modulation, including internalization assays and flow cytometric analyses after antibody treatment. These experiments confirmed both target engagement and functional consequences of antibody binding in vitro and validated its use in mouse models.

• Reagent grade: The antibody is described as purified, endotoxin-controlled, and validated for both in vitro (ELISA, flow cytometry, western blot) and in vivo applications by commercial suppliers, supporting its use in animal studies for targeting human CD25^+ cells.

• Species specificity: The antibody is specific to human CD25 and typically used in mice bearing human xenografts or humanized mice; it does not appreciably bind to mouse CD25.

• Common research purposes: Beyond radioimmunotherapy, 7G7B6 may be used in mouse models to deplete, block, or track human CD25^+ cells, such as studying immune cell dynamics, lymphoproliferative disease, and transplant or autoimmunity models involving human cells.

In summary: In in vivo mouse studies, clone 7G7B6 is most commonly used to target and manipulate human CD25^+ cells—especially in xenograft tumor models, where it has been deployed as a radiolabeled therapeutic and as a research tool for studying immune modulation.

The sterile packaged clone 7G7B6 (anti-human CD25 monoclonal antibody) should be stored at 2–8°C (refrigerated) for short-term use—typically at least 1 week, though some sources indicate stability for up to 1 month when kept sterile.

For long-term storage, it is recommended to aseptically aliquot the antibody without diluting it and freeze at –20°C to maximize stability and avoid repeated freeze-thaw cycles. Some sources specifically state stability at 4°C for up to 6 months, but freezing is still advised for the longest shelf life.

Summary Table

Always check the manufacturer’s datasheet for your specific lot, as recommendations can vary slightly by supplier and formulation.

In the literature, the 7G7B6 antibody, which targets human CD25 (IL-2R?), is often used in conjunction with other antibodies or proteins for various research applications. Here are some commonly used antibodies or proteins that are utilized alongside 7G7B6:

1. Anti-CCR7 Antibodies: These are used to study the CD25-CCR7 complex and its role in non-canonical IL-2 signaling. For example, biotin-anti-human CCR7 mouse monoclonal antibodies are used in conjunction with 7G7B6 to explore cellular interactions.

2. Anti-HA Antibodies: These are used for tagging and detecting proteins expressed with a hemagglutinin (HA) tag. Antibodies like 12CA5 or from BioLegend are commonly used for experimental purposes.

3. Immune Checkpoint Proteins: Although not directly used with 7G7B6 in the same experimental setup, immune checkpoint proteins like PD-1, PD-L1, and CTLA-4 are mentioned in the context of potential therapeutic applications involving CD25 targeting.

4. Anti-CD25 Antibodies (Other Clones): Other clones like MA251 and BC96 are used for comparing or complementing the 7G7B6 antibody in studies.

5. Fc-Optimized Anti-CD25 Antibodies: These are developed for enhanced ADCP or ADCC responses and are compared to existing therapeutic antibodies like Daclizumab and Basiliximab.

These antibodies and proteins are used in techniques such as flow cytometry, ELISA, and Western blotting to study cell surface markers and signaling pathways.

The key scientific findings regarding clone 7G7B6 primarily involve its use as a monoclonal antibody targeting human CD25, and its potential in preclinical therapeutic contexts.

• Specificity and Binding: 7G7B6 is a monoclonal antibody that specifically targets CD25 (the alpha chain of the interleukin-2 receptor, IL-2R?), a protein found on activated T cells and B cells. Studies show that radiolabeled forms of 7G7B6 retain high binding affinity for CD25-positive cells, with more than 80% of the added antibody binding to the target cells during in vitro assays. Unlabeled 7G7B6 can inhibit this binding, confirming specificity.

• Preclinical Therapeutic Evaluation: A key preclinical study evaluated a radioimmunotherapeutic agent consisting of 7G7B6 labeled with yttrium-90 (^90Y-7G7B6). This form was shown to:

  • Retain immunoreactivity and specificity for CD25-positive lymphoma cells.
  • Bind comparably to other radiolabels such as ^111In-7G7B6.
  • Internalize into target cells and induce modulation of CD25, according to both flow cytometry and internalization studies.
  • Overall, the study suggested that ^90Y-7G7B6 could be a promising agent for treating CD25-expressing lymphomas.

• Clinical Implications: The findings underscore the clone’s potential utility in both diagnostic and therapeutic settings, particularly in diseases characterized by CD25 expression, such as certain lymphomas.

• Summary Table

No prominent citations indicate the use of 7G7B6 in contexts outside of targeting CD25 or its application in immunotherapy and research into CD25-positive immune cells. If you seek data about 7G7B6 in other experimental models or alternative molecular contexts, the current literature primarily supports findings as summarized above.